Home »

ONL Therapeutics Closes Series A Financing to Support Development of Novel Retinal Cell Protection Platform for Treatment of Ocular Diseases

Proceeds to Support Final Development of ONL1204 in Preparation for Retinal Detachment Clinical Trials

Analytics

© 2020 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de